Diopter Technologies — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Diopter Technologies is a private, pre-revenue medical device innovator founded in 2021 and based in San Francisco. The company is pioneering a novel platform that integrates drug delivery and regenerative biologics into advanced contact lens and dissolving polymer devices for treating ocular surface disorders. Its lead programs include the PrismX drug-eluting contact lens and the Bioshare dissolving amniotic membrane device, with at least one clinical study recently completed. Diopter is positioning itself to address significant unmet needs in corneal repair and chronic eye disease treatment, aiming to improve patient compliance and clinical outcomes.

Ophthalmology

Technology Platform

Proprietary platform combining biocompatible/bio-dissolving polymers with amniotic membrane properties for drug delivery and ocular surface repair via contact lenses and dissolving devices.

Opportunities

The large and growing global market for corneal repair and chronic eye disease treatment, driven by an aging population and high incidence of ocular trauma, presents a major opportunity.

Diopter's non-surgical, patient-friendly devices could capture significant market share by improving compliance and outcomes over current standard-of-care treatments.

Risk Factors

Key risks include clinical trial failures, regulatory hurdles for novel combination products, challenges in achieving surgeon adoption and payer reimbursement, and competition from established and emerging therapies.

As a pre-revenue startup, dependence on external funding is a persistent financial risk.

Competitive Landscape

Diopter competes in the regenerative ophthalmology and advanced drug delivery segments. Competitors include companies developing amniotic membrane products (e.g., TissueTech, Amniox Medical), corneal implants, and drug-eluting contact lenses (e.g., Johnson & Johnson, Novartis). Diopter's differentiation lies in its dissolving polymer platform that integrates biologics, aiming to simplify treatment protocols.

More companies in Drug Delivery & Formulation →More companies in United States →